

Effects of Plant-Based Diet on Metabolic Parameters, Liver and Kidney Steatosis: A Prospective Interventional Open-label Study

Begum Guler Senturk¹, Bengi Gurses², Ceren Soyuturk³, Sidar Copur¹, Said Incir⁴, Dimitrie Siriopol⁵, Nuri Baris Hasbal⁶, Murat Akyildiz⁷, Daniel H van Raalte⁸, Mehmet Kanbay⁶

¹Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey

²Department of Radiology, Koc University School of Medicine, Istanbul, Turkey

³Clinical Dietician, Koc University Hospital, Istanbul, Turkey

⁴Department of Clinical Biochemistry, Koc University School of Medicine, Istanbul, Turkey

⁵Department of Nephrology, “Saint John the New” County Hospital, Suceava, Romania,

⁶Division of Nephrology, Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey

⁷Division of Gastroenterology, Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey

⁸Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Corresponding Author: Nuri Baris Hasbal, MD, Division of Nephrology, Department of Internal Medicine, Koc University School of Medicine, E-mail: nhasbal@ku.edu.tr Phone: +905353500415

Running title: Can plant-based diets be the solution to metabolic diseases?



This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI

10.1017/S0007114525000017

The British Journal of Nutrition is published by Cambridge University Press on behalf of The Nutrition Society

Abstract

This interventional single-center prospective open-label study aims to evaluate the effects of a vegan diet, compared to a vegetarian and omnivorous diet, on metabolic parameters, insulin sensitivity, and liver and kidney steatosis in healthy adults. The study included 53 omnivorous participants aged 18-40 years, body-mass index 18-30 kg/m², without any chronic disease, chronic medication use, active smoking, or significant alcohol consumption. All participants were omnivorous at baseline and selected to continue an omnivorous diet or transition to a vegetarian or vegan diet, with follow-up over six months. Anthropometric measurements, biochemical parameters, and liver and kidney steatosis were assessed at baseline and after six months using magnetic resonance imaging-proton density fat fraction (MRI-PDFF). Primary outcomes included changes in liver and kidney steatosis, while secondary outcomes were alterations in anthropometric and biochemical markers. Among 53 participants, 18 followed an omnivorous diet, 21 adopted a vegetarian diet, and 14 transitioned to a vegan diet. Dietary interventions did not result in statistically significant changes in body mass index, fat mass, fat percentage, or muscle mass over six months. However, statistically significant improvements in systolic and diastolic blood pressure, favoring the vegan diet, were observed. We aimed to control for potentially confounding variables to ensure the reliability of these findings. We have demonstrated a better decline in steatosis at the lower kidney pole, the total hilus and the Liver 6 index in vegans. We demonstrated that a plant-based diet is associated with improvements in several metabolic parameters and may reduce liver and kidney steatosis.

Keywords: Vegetarian diet, Non-alcoholic fatty liver disease, Chronic kidney disease, Steatosis, Hepatosteatorsis

Abbreviations

ALP - Alkaline Phosphatase; ALT - Alanine Aminotransferase; AST - Aspartate Aminotransferase; BMI - Body Mass Index; DBP - Diastolic Blood Pressure; HDL - High Density Lipoprotein; HOMA-IR - Homeostatic Model Assessment for Insulin Resistance; hs-CRP - High Sensitive C-Reactive Protein; LDL - Low Density Lipoprotein; MAFLD - Metabolic Dysfunction-Associated Fatty Liver Disease; MRI-PDFF - Magnetic Resonance Imaging-Proton Density Fat Fraction; NAFLD - Non-Alcoholic Fatty Liver Disease; SBP - Systolic Blood Pressure

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease globally. It has an estimated prevalence of 25.2% (1). Common risk factors include high fructose intake, diabetes mellitus, metabolic syndrome, hyperlipidemia, a Western-type diet, obesity, polycystic ovary syndrome, and obstructive sleep apnea (2, 3). Recently, NAFLD has been considered a component of the metabolic syndrome and referred to as metabolic dysfunction-associated fatty liver disease (MAFLD), with a range from simple steatosis to non-alcoholic steatosis (4). The most widely accepted pathophysiological explanation is the "two-hit hypothesis." The first hit involves lipid accumulation in the liver, primarily mediated by peripheral insulin resistance. The second hit is characterized by a pro-inflammatory, pro-oxidant, and pro-fibrotic immune response to this accumulation (3, 5-7). Since there are no approved pharmacotherapies available for the treatment of NAFLD, dietary and lifestyle modifications are the mainstay of preventive and therapeutic approaches for patients with or at risk of NAFLD (8, 9). Despite growing concern about the pathophysiological and therapeutic roles of dietary habits in NAFLD and insulin resistance, there is no consensus regarding the recommended dietary routine. A systematic review of 48 studies, including 12 cohort studies and 36 cross-sectional studies, reported that vegan diets are lower in protein intake and certain micronutrients (i.e., vitamin B12, riboflavin, niacin, calcium, selenium, zinc, and iodine) compared to omnivorous diets, though these intakes generally meet daily requirements (10, 11). Large-scale clinical studies have demonstrated that vegetarian or vegan diets are associated with considerable protection against cardiovascular disease, metabolic syndrome, insulin resistance, and chronic kidney disease (12-15). Multiple randomized controlled trials have also shown that vegan diets positively affect body fat composition and insulin sensitivity (16-18). Patients with chronic kidney disease who incorporated plant-based proteins into their diet demonstrated a reduced incidence of disease progression and mortality (19, 20). A recent study revealed that lacto-ovo-vegetarian diet leads to improvements in liver health markers, such as reductions in liver enzymes, in individuals with NAFLD (21). With this background in mind, in this prospective study, we aimed to evaluate the effects of plant-based diets, specifically vegetarian and vegan diets, compared to omnivore diets on multiple variables, including the steatosis of the liver and kidneys, biochemical parameters including serum lipid profile, liver enzymes, and insulin resistance, and clinical parameters such as blood pressure (BP), body mass index, and body fat or muscle mass.

Materials and Methods

We have designed an interventional open-label prospective study investigating the effects of three different diets—omnivorous, vegetarian, and vegan—on multiple health outcomes over a six-month period (October 2021-July 2022). Both the intervention and follow-up were conducted during this six-month timeframe. This study adhered to the guidelines of the Declaration of Helsinki, and all procedures involving human subjects were approved by the Koç University School of Medicine (2021.216.IRB1.073). Written informed consent was obtained from all patients. Trial registration number: NCT05351853.

Participants Selection:

Participants were recruited through an online application form, which was advertised via social media platforms such as X (formerly known as Twitter), Instagram, and institutional announcements. The form included detailed information about the study's aim, design, follow-up periods, and the primary and secondary outcomes being investigated. Applicants were then contacted via telephone interviews, during which further details about the study procedures were provided. The inclusion criteria included participants aged 18 to 40 with a body mass index (BMI) of 18–30 kg/m² who were omnivorous at baseline. The exclusion criteria included a history of chronic systemic diseases (such as cardiovascular disease, diabetes, chronic kidney disease, chronic respiratory disease, inflammatory bowel disease, liver disease, autoimmune disorders like rheumatoid arthritis), chronic medication use, active smoking, and alcohol consumption exceeding 10 grams/day for females and 20 grams/day for males. Participants following a vegan or vegetarian diet at baseline were also excluded.

Participants were assigned to the omnivorous, vegetarian, or vegan diet groups based on their preferences, as randomization was not feasible due to the challenges of maintaining adherence to specific dietary interventions. All participants were omnivorous at baseline and were given the choice to either continue with their omnivorous diet or transition to a vegetarian or vegan diet, according to their willingness and interest. This self-selection approach allowed participants to align their choice with personal dietary preferences, which may have supported adherence throughout the study period. To control for potential baseline differences, participants were matched by age, gender, and BMI. Informed consent was obtained from all participants.

The minimum sample size required to conduct this interventional study was calculated to be 31, with a confidence interval of 95% and a prevalence of veganism of 2% in the general population (22, 23). The study flowchart is presented in Figure 1.

Study Design and Investigated Parameters:

Participants were divided into three groups based on their dietary preferences: (1) those who continued their omnivorous diet, (2) those who switched to a vegetarian diet, and (3) those who switched to a vegan diet. All participants were counseled by the same nutritional specialist at baseline and monthly thereafter. Counseling sessions included guidance on dietary patterns, daily calorie needs (calculated via the Schofield formula) (24), daily exercise routines, macro- and micronutrients, and diet. While no specific food or beverage restrictions were imposed, participants were expected to adhere to their assigned dietary group. There was no upper limit on daily caloric intake as long as the prescribed diet was followed.

Participants' adherence to their assigned diet was systematically monitored each month through qualitative assessments (in-depth interviews) and quantitative assessments (mean daily caloric intake), based on three-day food logs kept by participants at monthly intervals. A registered dietitian met with each participant monthly, during which three-day food logs were completed at each session, resulting in six logs over the study period. These logs were used to calculate compliance with the prescribed diet, allowing adherence levels to be quantified for each dietary group. All groups demonstrated high compliance with their assigned diets throughout the study, as observed through monthly food logs and qualitative assessments conducted by the dietitian. Additionally, participants' physical activity was tracked using a mobile phone application that recorded daily step counts. Counseling sessions included general recommendations for physical activity, which participants were encouraged to follow. Baseline physical activity levels are reported in Table 1, and changes in activity were monitored and assessed at both baseline and the six-month follow-up to capture any shifts over the study period.

Clinical parameters evaluated in our study included BP measurements, BMI assessment, and body fat and muscle mass assessment via the Tanita MC-780 S Black Segmental Body Composition Analyzer. This device uses bioelectrical impedance analysis (BIA) to assess body composition. Biochemical parameters investigated in this study included the complete blood count, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), direct bilirubin, high sensitive C-reactive protein (hs-

CRP), creatinine, blood urea nitrogen, fasting glucose and insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), uric acid, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and urinary albumin-to-creatinine ratio (Microalbuminuria). Those clinical and biochemical parameters were evaluated at baseline and six-month follow-up visits.

Liver and kidney steatosis were evaluated at baseline and at the six-month follow-up using magnetic resonance imaging (MRI) with the proton density fat fraction (PDFF) technique, which estimates fat content in tissues. The MRI-PDFF technique is one of the most accurate non-invasive methods for assessing steatosis, with a strong correlation to histopathological findings and the ability to quantify steatosis (25, 26).

Statistical Analysis:

Data are presented as mean \pm standard deviation, median with interquartile range or number and percent frequency, as appropriate. The comparison between groups was performed using the Chi-square test for categorical variables and the Kruskal-Wallis, One-Way Anova, Mann-Whitney or independent t test for the remaining variables, as appropriate. The normality of the distribution was assessed using the Shapiro-Wilk test.

Time repeated measurements were analyzed using linear mixed models including group, time, and the group by time interaction term. Normally distributed continuous variables were assessed through mixed models for repeated measurements, and for non-normally distributed data, penalized quasi-likelihood under restricted maximum likelihood models was applied. All models were adjusted for baseline values, daily average calories, daily average protein intake, and daily step counts at baseline and six months. A P-value of less than 0.05 was considered statistically significant. Power analysis was performed to determine the minimum number of participants needed for the study, as described previously. All analyses were conducted using Stata MP Software, version 13 (Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).

Results

Baseline characteristics:

The total number of participants who completed the study was 53, divided into 18, 21, and 14 participants in the omnivorous, vegetarian, and vegan groups, respectively, with differences due to participant dropout throughout the study period (Figure 1). Baseline

demographic, clinical, imaging, and biochemical characteristics are presented in Table 1. An overall comparison across the three groups indicated a significant difference in daily protein intake ($p=0.04$), with the omnivorous group having a higher mean protein intake compared to the vegetarian group. There were no other significant differences between the three groups.

Changes in Anthropometric and Clinical Parameters During Follow-Up:

Firstly, we assessed the changes in BMI, body compartments, systolic BP, and diastolic BP at the six-month follow-up (see Table 2). No significant changes in BMI, fat mass, fat percentage, or muscle mass were observed between the three groups during the follow-up period. However, a significant difference in the slope of fat-free mass change was observed between the three groups (0.97, 95% CI 0.19 to 1.75, -0.03, 95% CI -0.76 to 0.69, and -0.89, 95% CI -1.78 to -0.01 for the omnivorous, vegetarian, and vegan groups, respectively). Similar results were observed for fat mass. By contrast, systolic and diastolic BP decreased significantly at six months, with a significant difference in the slope of decrease between the three groups (Figure 2). Additionally, there was no statistically significant change in daily step counts between baseline and six months across the groups.

Changes in Biochemical Parameters During Follow-Up:

We have analyzed the evolution of different biochemical analyses during the 6 months of intervention. No significant differences were observed in liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], or total and direct bilirubin) or hemoglobin levels (Table 3). However, a significant difference in the slope of change for serum glucose and insulin was observed, though no significant changes in HOMA-IR were noted.

Regarding the lipid levels, there were no significant changes in total cholesterol values. However, HDL and LDL cholesterol levels decreased more significantly in the vegan group during the follow-up. Additionally, there was a significant decrease in eGFR levels, with a significant difference in the slope between the three groups (Table 3).

Changes at Liver and Kidney Steatosis on Imaging During Follow-Up:

Lastly, a significant difference in the slope of change in kidney steatosis at the lower pole was identified between the three groups (Figure 3A and B). No other significant differences in kidney parameters were observed. For liver parameters, significant differences in the slope

of change were observed for the total hilus ($p=0.008$) and the Liver 6 indexes ($p=0.04$) (Figure 3C and D).

Discussion

We performed a single-center prospective study in fifty-three participants, to investigate the effects of three major dietary patterns on various anthropometric and biochemical parameters, as well as liver and kidney steatosis, assessed using the MRI-PDFP technique at the six-month follow-up. Analysis of the results showed no significant changes in BMI, fat mass, fat percentage, or muscle mass between the three dietary groups.

Our findings indicated that the vegan diet was associated with statistically significant improvements in liver steatosis, particularly at segment 6 of the liver, and reductions in kidney steatosis at the lower pole. Additionally, participants on a vegan diet showed decreases in LDL and HDL cholesterol and improvements in both systolic and diastolic BP. In contrast, no significant changes were observed in the vegetarian group. This lack of change in the vegetarian group may be partly attributable to the inclusion of dairy and eggs, which contain saturated fats and cholesterol that could attenuate improvements in metabolic parameters. Saturated fats have been linked to hepatic fat accumulation, and dietary cholesterol may influence lipid levels, potentially contributing to less favorable effects on liver and cardiovascular outcomes compared to a fully plant-based diet (27). Further, the statistically significant increase in eGFR observed in the vegan and vegetarian groups may be partly due to improvements in “fatty kidney” status, as reduced fat deposits in renal tissues have been linked to better kidney function (28). Additionally, the lower acid load associated with plant-based diets may have contributed to these findings, as a reduced dietary acid load can lessen renal acid excretion demands, potentially preserving kidney function (29, 30).

Dietary and lifestyle modifications are the cornerstone of both the preventive and therapeutic approach towards NAFLD; however, the optimal dietary modifications remain under investigation. Vegetarian and vegan diets, which emphasize whole grains, vegetables, fruits, legumes, and nuts, have shown promising benefits for liver health, with several studies associating these diets with reductions in hepatic steatosis, improved liver enzyme levels, and better metabolic outcomes in patients with NAFLD (31-33). These plant-based diets are low in saturated fats and dietary cholesterol, which may reduce fat accumulation in the liver and improve lipid profiles, potentially contributing to a lower risk of insulin resistance and inflammation (34). Studies have also suggested that plant-based diets may lower oxidative stress, support favorable changes in the gut microbiome, and improve glucose metabolism,

further aiding in NAFLD management (32, 35). While direct comparisons between vegetarian, vegan, and other diets in NAFLD are limited, the unique nutrient composition of plant-based diets—high in fiber, antioxidants, and phytochemicals—may offer a protective effect on liver function.

To the best of our knowledge, our prospective study is the first study investigating the role of various dietary modalities on renal steatosis. Our prospective study is among the few to examine the effects of vegetarian and vegan diets on hepatic and renal steatosis using MRI-PDFF, a non-invasive assessment method (36). Although some data are available on dietary patterns for liver health, data on renal steatosis remain sparse (37). Recent research suggests that increased renal steatosis is linked to higher risks of chronic kidney disease (CKD) and cardiovascular events, underscoring the clinical relevance of our study (35).

A recent open-label prospective study including 40 patients with NAFLD demonstrated significant improvements in liver enzymes, with ALT decreasing from 99 U/L (SD \pm 45) to 36 U/L (SD \pm 21) and AST from 54 U/L (SD \pm 44) to 27 U/L (SD \pm 10) after six months on a strict vegan diet (38). However, this study was limited by the lack of a control group, a high dropout rate (14 patients, 35%), and no evaluation of hepatosteatois. In contrast, our study included participants without liver disease at baseline, so ALT and AST levels were already within the normal range, resulting in only modest reductions among vegan participants. Our study's dropout rate in the vegan group was similar at 30%, but our inclusion of a control group allowed for broader comparisons across dietary interventions. A randomized controlled trial of 244 participants, using proton magnetic resonance spectroscopy to assess lipids, assigned participants to a low-fat vegan or regular diet for sixteen weeks and found significant improvements in body weight (-5.9 kg; $p < 0.001$), insulin sensitivity (HOMA-IR -1.3 ; $p < 0.001$), and reductions in hepatocellular (-34.4% ; $p = 0.002$) and intramyocellular lipids (-10.4% ; $p = 0.03$) in the vegan group (16). Our study, conducted over six months in participants without baseline liver disease, found modest reductions in liver fat due to already-normal HOMA-IR and hepatic lipid levels at baseline. While both studies highlight metabolic benefits of a vegan diet, ours uniquely assessed renal steatosis using MRI-PDFF.

Even though the exact biochemical and pathophysiological mechanisms leading to difference in terms of various dietary habits are largely unknown, there are multiple hypothesis in this regard. Plant-based diets typically contain higher proportions of unsaturated fatty acids and are rich in dietary fiber and phytosterols, which have been shown

to reduce LDL cholesterol and improve lipid profiles, reducing the lipid accumulation that contributes to liver steatosis (39, 40). Additionally, plant-based fats, dietary fiber, and phytochemicals exhibit anti-inflammatory effects that modulate gut microbiota composition, potentially reducing systemic inflammation—a factor implicated in both liver and kidney disease progression (41-44). A lower salt load in plant-based diets has been shown to help maintain kidney function by reducing hypertension, while the absence of heme iron may reduce oxidative stress, a known contributor to liver and kidney damage (45, 46).

Our prospective study has several important considerations limiting the generalizability of our results. First, the six-month follow-up period may have limited our ability to detect long-term changes in outcomes such as liver and kidney steatosis, as well as sustained alterations in anthropometric and biochemical parameters. Second, although MRI-PDF is highly reliable, histopathological assessment remains the gold standard for evaluating liver and kidney steatosis (47, 48). Additionally, the lack of dietary compliance assessment remains a significant limitation in our study. Participants self-selected into each diet group, potentially introducing variability in adherence due to differing health motivations and perceptions. Participants choosing to maintain their usual omnivorous diet may have been less inclined to modify their dietary habits, possibly reflecting fewer immediate health concerns or a preference for continuity rather than dietary change. In contrast, those selecting vegetarian or vegan diets may have been motivated by a desire to improve health outcomes, potentially related to unreported or subclinical health issues. This variability in motivation could have influenced adherence levels across groups, as participants actively seeking dietary change may demonstrate greater compliance with the intervention. Future studies could address this by employing randomized group assignments or standardized adherence monitoring to better evaluate the effects of dietary interventions. Moreover, a detailed assessment of dietary compliance represents a limitation in this study. Although monthly nutritional diaries were collected and examined, it was possible to evaluate only general dietary patterns rather than precise quantities and specific nutritional content. Consequently, an accurate assessment of macronutrient and micronutrient intake across omnivorous, vegetarian, and vegan groups was not feasible, limiting the capacity to evaluate adherence comprehensively. Moreover, although there is a male predominance among omnivore group participants (66.7%) compared to vegetarian (33.3%) and vegan group (35.7%), we have adjusted for this relative imbalance in our analysis. Also, our analysis lack data regarding the daily micro and macronutrient intake of participants from different groups as well as lack of

standardized method to assess the dietary adherence except from interviews and three-day food intake logbooks. Lastly, the statistically higher daily caloric intake may potentially contribute to the differences regarding the adipose tissue measurements on MRI scans. Nevertheless, the results of our prospective study are significant and could potentially enlighten future clinical trials that would investigate the effects of dietary habits on multiple clinical parameters and endpoints.

Acknowledgements

Financial Support: None

Conflict of Interest: The authors declare that there are no conflicts of interest.

Authorship: BGS, BG, CS, SC, SI, NBH: substantial contributions to the conception and design, data acquisition, analysis and/or interpretation, drafting the article, and critically revising it for important intellectual content. DS, NBH, MA, DHvR, MK: drafting the article and critically revising it for important intellectual content. All authors have approved the final version to be published and agree to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References:

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64(1):73-84.
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64(1):73-84.
3. Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. *Chin Med J (Engl)*. 2020;134(1):8-19.
4. Sangro P, de la Torre Aláez M, Sangro B, D'Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. *J Physiol Biochem*. 2023.

5. Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. *Diabetes Obes Metab*. 2017;19(11):1630-4.
6. Day CP, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology*. 1998;114(4):842-5.
7. Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". *World J Gastroenterol*. 2018;24(27):2974-83.
8. Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2021;17(8):484-95.
9. Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. *Front Biosci (Landmark Ed)*. 2021;26(2):206-37.
10. Bakaloudi DR, Halloran A, Rippin HL, Oikonomidou AC, Dardavesis TI, Williams J, et al. Intake and adequacy of the vegan diet. A systematic review of the evidence. *Clin Nutr*. 2021;40(5):3503-21.
11. Weikert C, Trefflich I, Menzel J, Obeid R, Longree A, Dierkes J, et al. Vitamin and Mineral Status in a Vegan Diet. *Dtsch Arztebl Int*. 2020;117(35-36):575-82.
12. Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies. *Crit Rev Food Sci Nutr*. 2017;57(17):3640-9.
13. Marrone G, Guerriero C, Palazzetti D, Lido P, Marolla A, Di Daniele F, et al. Vegan Diet Health Benefits in Metabolic Syndrome. *Nutrients*. 2021;13(3).
14. Sakkas H, Bozidis P, Touzios C, Kolios D, Athanasiou G, Athanasopoulou E, et al. Nutritional Status and the Influence of the Vegan Diet on the Gut Microbiota and Human Health. *Medicina (Kaunas)*. 2020;56(2).
15. Gluba-Brzózka A, Franczyk B, Rysz J. Vegetarian Diet in Chronic Kidney Disease-A Friend or Foe. *Nutrients*. 2017;9(4).
16. Kahleova H, Petersen KF, Shulman GI, Alwarith J, Rembert E, Tura A, et al. Effect of a Low-Fat Vegan Diet on Body Weight, Insulin Sensitivity, Postprandial Metabolism, and Intramyocellular and Hepatocellular Lipid Levels in Overweight Adults: A Randomized Clinical Trial. *JAMA Netw Open*. 2020;3(11):e2025454.

17. Crosby L, Rembert E, Levin S, Green A, Ali Z, Jardine M, et al. Changes in food and nutrient intake and diet quality on a low-fat vegan diet are associated with changes in body weight, body composition, and insulin sensitivity in overweight adults: a randomized clinical trial. *Journal of the Academy of Nutrition and Dietetics*. 2022;122(10):1922-39. e0.
18. Kahleova H, Tura A, Hill M, Holubkov R, Barnard ND. A plant-based dietary intervention improves beta-cell function and insulin resistance in overweight adults: a 16-week randomized clinical trial. *Nutrients*. 2018;10(2):189.
19. Alvirdizadeh S, Yuzbashian E, Mirmiran P, Eghtesadi S, Azizi F. A prospective study on total protein, plant protein and animal protein in relation to the risk of incident chronic kidney disease. *BMC nephrology*. 2020;21(1):1-7.
20. Wu C-L, Tsai W-H, Liu J-S, Liu H-W, Huang S-Y, Kuo K-L. Vegan Diet Is Associated with a Lower Risk of Chronic Kidney Disease in Patients with Hyperuricemia. *Nutrients*. 2023;15(6):1444.
21. Garousi N, Tamizifar B, Pourmasoumi M, Feizi A, Askari G, Clark CC, et al. Effects of lacto-ovo-vegetarian diet vs. standard-weight-loss diet on obese and overweight adults with non-alcoholic fatty liver disease: a randomised clinical trial. *Archives of Physiology and Biochemistry*. 2023;129(4):975-83.
22. Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. *Gastroenterol Hepatol Bed Bench*. 2013;6(1):14-7.
23. Paslakis G, Richardson C, Nöhre M, Brähler E, Holzapfel C, Hilbert A, et al. Prevalence and psychopathology of vegetarians and vegans - Results from a representative survey in Germany. *Sci Rep*. 2020;10(1):6840.
24. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. *Human nutrition Clinical nutrition*. 1985;39:5-41.
25. Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. *Eur Radiol*. 2019;29(7):3564-73.
26. Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. *Hepatology*. 2018;68(2):763-72.
27. Ozen E, Mihaylova R, Weech M, Kinsella S, Lovegrove JA, Jackson KG. Association between dietary saturated fat with cardiovascular disease risk markers and body composition in healthy adults: Findings from the cross-sectional BODYCON study. *Nutrition & Metabolism*. 2022;19(1):15.

28. Seng NSHL, Lohana P, Chandra S, Jim B. The fatty kidney and beyond: a silent epidemic. *The American Journal of Medicine*. 2023.
29. Mofrad MD, Daneshzad E, Azadbakht L. Dietary acid load, kidney function and risk of chronic kidney disease: A systematic review and meta-analysis of observational studies. *International Journal for Vitamin and Nutrition Research*. 2019.
30. Kim H, Caulfield LE, Garcia-Larsen V, Steffen LM, Grams ME, Coresh J, et al. Plant-based diets and incident CKD and kidney function. *Clinical Journal of the American Society of Nephrology*. 2019;14(5):682-91.
31. Le LT, Sabaté J. Beyond meatless, the health effects of vegan diets: findings from the Adventist cohorts. *Nutrients*. 2014;6(6):2131-47.
32. Castelnovo G, Perez-Diaz-del-Campo N, Rosso C, Armandi A, Caviglia GP, Bugianesi E. A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease. *Nutrients*. 2024;16(13):2027.
33. Chiarioni G, Popa S-L, Dalbeni A, Senore C, Leucuta DC, Baroni L, et al. Vegan Diet Advice Might Benefit Liver Enzymes in Nonalcoholic Fatty Liver Disease: an Open Observational Pilot Study. *Journal of Gastrointestinal & Liver Diseases*. 2021;30(1).
34. Kahleova H, Fleeman R, Hlozkova A, Holubkov R, Barnard ND. A plant-based diet in overweight individuals in a 16-week randomized clinical trial: metabolic benefits of plant protein. *Nutrition & diabetes*. 2018;8(1):58.
35. Sidhu SRK, Kok CW, Kunasegaran T, Ramadas A. Effect of plant-based diets on gut microbiota: a systematic review of interventional studies. *Nutrients*. 2023;15(6):1510.
36. Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. *European radiology*. 2019;29:3564-73.
37. Ajjarapu AS, Hinkle SN, Li M, Francis EC, Zhang C. Dietary patterns and renal health outcomes in the general population: a review focusing on prospective studies. *Nutrients*. 2019;11(8):1877.
38. Chiarioni G, Popa SL, Dalbeni A, Senore C, Leucuta DC, Baroni L, et al. Vegan Diet Advice Might Benefit Liver Enzymes in Nonalcoholic Fatty Liver Disease: an Open Observational Pilot Study. *J Gastrointestin Liver Dis*. 2021;30(1):81-7.
39. Abumweis S, Barake R, Jones P. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. *Food & nutrition research*. 2008;52(1):1811.

40. Satija A, Hu FB. Plant-based diets and cardiovascular health. *Trends in cardiovascular medicine*. 2018;28(7):437-41.
41. Trautwein EA, McKay S. The Role of Specific Components of a Plant-Based Diet in Management of Dyslipidemia and the Impact on Cardiovascular Risk. *Nutrients*. 2020;12(9).
42. Najjar RS, Moore CE, Montgomery BD. A defined, plant-based diet utilized in an outpatient cardiovascular clinic effectively treats hypercholesterolemia and hypertension and reduces medications. *Clin Cardiol*. 2018;41(3):307-13.
43. Carrero JJ, González-Ortiz A, Avesani CM, Bakker SJL, Bellizzi V, Chauveau P, et al. Plant-based diets to manage the risks and complications of chronic kidney disease. *Nat Rev Nephrol*. 2020;16(9):525-42.
44. Satija A, Hu FB. Plant-based diets and cardiovascular health. *Trends Cardiovasc Med*. 2018;28(7):437-41.
45. Joshi S, McMacken M, Kalantar-Zadeh K. Plant-based diets for kidney disease: a guide for clinicians. *American Journal of Kidney Diseases*. 2021;77(2):287-96.
46. Mancardi D, Mezzanotte M, Arrigo E, Barinotti A, Roetto A. Iron overload, oxidative stress, and ferroptosis in the failing heart and liver. *Antioxidants*. 2021;10(12):1864.
47. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. *Aliment Pharmacol Ther*. 2012;36(1):22-9.
48. Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. *Radiology*. 2015;274(2):416-25.

Table 1. Baseline characteristics of the study population

| | Total (N=53) | Omnivore (N=18) | Vegetarian (N=21) | Vegan (N=14) | P |
|-----------------------------|-------------------------|----------------------------|------------------------------|-------------------------|-------------|
| Age, years | 29.8±5.9 | 30.2±5.9 | 29.3±5.8 | 29.9±6.2 | 0.89 |
| Male, N (%) | 24 (45.3) | 12 (66.7) | 7 (33.3) | 5 (35.7) | 0.08 |
| Daily average calories, cal | 1468 (1120-1790) | 1515 (1150-1790) | 1450 (1230-1780) | 1405 (1250-1770) | 0.94 |
| Daily protein intake, g | 50.9±10.4 | 55.1±8.2 | 46.9±10.6 | 51.8±10.9 | 0.04 |
| Daily steps, *1000 | 13.6±3.3 | 13.1±3.3 | 14.0±3.1 | 13.6±3.7 | 0.71 |
| BMI, kg/m ² | 24.8±3.4 | 25.2±3.5 | 24.5±3.6 | 24.6±3.2 | 0.82 |
| Fat mass, kg | 18.6±6.5 | 18.9±5.8 | 18.9±7.9 | 16.7±5.3 | 0.84 |
| Fat percentage, (%) | 25.6±6.9 | 25.4±6.9 | 26.1±8.3 | 25.2±4.4 | 0.92 |
| Obesity degree, (%) | 10.0±14.8 | 11.4±14.5 | 9.6±16.7 | 8.9±12.9 | 0.88 |
| Fat free mass, kg | 53.8±11.3 | 56.9±11.1 | 52.3±11.3 | 52.0±11.3 | 0.36 |
| Muscle mass, kg | 51.8±10.7 | 54.1±10.6 | 51.4±10.8 | 49.4±10.8 | 0.47 |
| SBP, mmHg | 117.6±10.3 | 121.7±8.4 | 114.8±10.3 | 116.8±11.5 | 0.11 |
| DBP, mmHg | 73.9±6.5 | 76.1±5.8 | 73.6±5.0 | 71.8±8.5 | 0.16 |
| Total hilus | 2.8 (1.9-4.8) | 2.3 (1.9-3.7) | 3.0 (1.8-6.1) | 3.1 (2.7-5.4) | 0.28 |
| Liver2, (%) | 2.0 (1.7-3.5) | 2.1 (1.8-3.5) | 1.8 (1.6-5.4) | 2.1 (1.5-3.3) | 0.69 |
| Liver 4b, (%) | 1.9 (1.6-4.4) | 1.9 (1.6-3.8) | 1.8 (1.4-5.8) | 2.0 (1.4-3.3) | 0.98 |
| Liver 4a, (%) | 2.0 (1.6-3.4) | 2.1 (1.7-3.0) | 1.8 (1.6-4.6) | 1.9 (1.5-3.3) | 0.81 |
| Liver 8, (%) | 2.3 (1.8-4.6) | 2.5 (1.9-4.3) | 2.3 (1.8-4.9) | 2.2 (1.5-3.8) | 0.82 |
| Liver 7, (%) | 2.2 (1.6-3.7) | 2.3 (1.9-2.5) | 2.1 (1.6-4.4) | 1.9 (1.2-3.7) | 0.62 |
| Liver 3, (%) | 2.0 (1.6-3.6) | 2.1 (1.9-3.2) | 1.7 (1.5-3.9) | 1.8 (1.5-3.9) | 0.66 |
| Liver 5, (%) | 2.1 (1.5-3.9) | 2.1 (1.8-2.9) | 2.0 (1.4-5.2) | 2.2 (1.4-3.8) | 0.94 |
| Liver 6, (%) | 2.2 (1.7-3.6) | 2.3 (1.9-2.8) | 2.0 (1.7-6.8) | 2.4 (1.3-3.6) | 0.85 |
| Liver 1, (%) | 2.2 (1.7-4.0) | 2.2 (1.8-3.1) | 1.9 (1.6-4.7) | 2.2 (1.5-4.0) | 0.91 |
| Kidney upper, (%) | 1.6 (1.3-2.0) | 1.7 (1.3-2.4) | 1.5 (1.3-1.8) | 1.7 (1.4-2.2) | 0.37 |
| Kidney mid, (%) | 1.6 (1.4-1.9) | 1.6 (1.3-2.2) | 1.5 (1.4-1.9) | 1.8 (1.5-1.9) | 0.59 |
| Kidney lower, (%) | 1.6 (1.4-2.0) | 1.6 (1.4-1.7) | 1.5 (1.3-1.8) | 1.9 (1.5-2.1) | 0.25 |
| Kidney total, (%) | 1.5 (1.3-2.0) | 1.9 (1.5-2.2) | 1.4 (1.2-1.8) | 1.6 (1.3-1.9) | 0.14 |

BMI – body mass index; DBP – diastolic blood pressure; SBP – systolic blood pressure

P: The p-value for each characteristic represents an overall comparison across omnivorous, vegetarian, and vegan groups.

Table 2. Body mass index, body compartments and systolic and diastolic blood pressure evolution during the follow-up across the three groups

| | Baseline | 6 Months | p* | p[†] |
|------------------------------|---------------------|---------------------|--------------|----------------------|
| BMI, kg/m² | | | | |
| Omnivore(N=18) | 25.2 (23.6-26.8) | 25.8 (24.2-27.4) | 0.49 | 0.52 |
| Vegetarian (N=21) | 24.5 (23.0-26.0) | 24.8 (23.3-26.3) | | |
| Vegan (N=14) | 24.6 (22.8-26.4) | 24.8 (22.9-26.6) | | |
| p [‡] | - | 0.61 | | |
| Fat mass, | | | | |
| Omnivore (N=18) | 18.9 (16.1-21.8) | 19.9 (16.9-22.7) | 0.58 | 0.02 |
| Vegetarian (N=21) | 18.9 (16.2-21.5) | 19.4 (16.7-22.0) | | |
| Vegan (N=14) | 17.7 (14.4-20.9) | 17.1 (13.8-20.3) | | |
| p [‡] | - | 0.002 | | |
| Fat percentage | | | | |
| Omnivore (N=18) | 25.4 (22.5-28.4) | 25.7 (22.7-28.7) | 0.25 | 0.51 |
| Vegetarian (N=21) | 26.1 (23.3-28.8) | 26.6 (23.9-29.3) | | |
| Vegan (N=14) | 25.2 (21.8-28.5) | 24.9 (21.6-28.3) | | |
| p [‡] | - | 0.37 | | |
| Fat free mass | | | | |
| Omnivore(N=18) | 56.9 (51.9-61.9) | 57.9 (52.9-62.9) | 0.32 | 0.004 |
| Vegetarian(N=21) | 52.3 (47.7-56.9) | 52.3 (47.6-56.9) | | |
| Vegan (N=14) | 52.1 (46.4-57.8) | 51.2 (45.5-56.9) | | |
| p [‡] | - | <0.001 | | |
| Muscle mass | | | | |
| Omnivore(N=18) | 54.1 (49.1-59.1) | 53.2 (48.2-58.3) | 0.01 | 0.61 |
| Vegetarian (N=21) | 51.4 (46.8-56.1) | 49.6 (44.9-54.3) | | |
| Vegan (N=14) | 49.5 (43.8-55.1) | 48.7 (43.1-54.4) | | |
| p [‡] | | 0.81 | | |
| SBP, mmHg | | | | |
| Omnivore(N=18) | 121.7 (117.4-125.9) | 122.8 (118.5-127.1) | 0.04 | 0.01 |
| Vegetarian (N=21) | 114.8 (110.8-118.7) | 113.3 (109.3-117.3) | | |
| Vegan (N=14) | 116.8 (111.9-121.7) | 110.4 (105.5-115.2) | | |
| p [‡] | - | <0.001 | | |
| DBP, mmHg | | | | |
| Omnivore(N=18) | 76.1 (73.4-78.8) | 77.2 (74.5-79.9) | 0.002 | 0.004 |
| Vegetarian (N=21) | 73.6 (71.1-76.1) | 71.4 (68.9-73.9) | | |
| Vegan (N=14) | 71.8 (68.7-74.8) | 67.1 (64.1-70.2) | | |
| p [‡] | - | <0.001 | | |

Data are presented as mean (95%CI) at baseline, and least-squares mean (95%CI) at 6 months. Analysis was conducted using a mixed model for repeated measures, adjusting for baseline values and for baseline and 6 months daily average calories, daily average proteins and daily steps.

*P value for time effect – trend over time in all arms

[†]P value for treatment x time interaction – evaluates if changes in one group are different from the changes in other groups

[‡]P value for comparison between groups at each moment

BMI – body mass index; DBP – diastolic blood pressure; SBP – systolic blood pressure.

Table 3. Biological parameters, liver and kidney PDFF values evolution during the follow-up across the three groups

| | Baseline | 6 Months | p* | p[†] |
|---------------------------------|---------------------|---------------------|-------------|----------------------|
| Serum glucose, mg/dL | | | | |
| Omnivore (N=18) | 90.4 (87.2-93.6) | 94.5 (91.3-97.7) | 0.71 | 0.006 |
| Vegetarian (N=21) | 91.9 (88.9-94.8) | 91.6 (88.7-94.6) | | |
| Vegan (N=14) | 91.8 (88.2-95.4) | 90.2 (86.6-93.8) | | |
| p [‡] | - | 0.001 | | |
| Insulin, µU/ml | | | | |
| Omnivore (N=18) | 10.5 (5.8-15.2) | 16.8 (12.0-21.5) | 0.71 | 0.006 |
| Vegetarian (N=21) | 10.5 (6.1-14.9) | 8.7 (4.3-13.1) | | |
| Vegan (N=14) | 8.9 (3.5-14.3) | 6.9 (1.5-12.3) | | |
| p [‡] | - | 0.001 | | |
| HOMA score | | | | |
| Omnivore (N=18) | 2.4 (1.3-3.4) | 3.3 (2.2-4.3) | 0.59 | 0.13 |
| Vegetarian (N=21) | 2.4 (1.5-3.4) | 2.4 (1.4-3.4) | | |
| Vegan (N=14) | 2.1 (0.9-3.3) | 1.5 (0.3-2.7) | | |
| p [‡] | - | 0.10 | | |
| Total cholesterol, mg/dL | | | | |
| Omnivore (N=18) | 178.4 (162.4-194.4) | 175.8 (159.8-191.8) | 0.18 | 0.13 |
| Vegetarian (N=21) | 171.2 (156.4-186.1) | 169.4 (154.6-184.2) | | |
| Vegan (N=14) | 178.4 (160.2-196.5) | 160.5 (142.4-178.6) | | |
| p [‡] | - | 0.01 | | |
| HDL cholesterol, mg/dL | | | | |
| Omnivore (N=18) | 54.7 (49.1-60.4) | 56.5 (50.9-62.1) | 0.19 | 0.04 |
| Vegetarian (N=21) | 63.0 (57.8-68.3) | 60.4 (55.2-65.6) | | |
| Vegan (N=14) | 60.2 (53.8-66.6) | 55.4 (48.9-61.7) | | |
| p [‡] | - | 0.001 | | |
| LDL cholesterol, mg/dL | | | | |
| Omnivore (N=18) | 117.9 (102.9-132.8) | 117.4 (102.4-132.4) | 0.04 | 0.006 |
| Vegetarian (N=21) | 105.8 (92.0-119.6) | 104.0 (90.3-117.8) | | |
| Vegan (N=14) | 119.1 (102.2-136.0) | 101.4 (84.5-118.3) | | |
| p [‡] | - | <0.001 | | |
| Triglycerides, mg/dL | | | | |
| Omnivore (N=18) | 79.6 (58.9-100.3) | 75.4 (54.4-96.4) | 0.08 | 0.91 |
| Vegetarian (N=21) | 75.4 (54.4-96.4) | 87.3 (68.2-106.5) | | |
| Vegan (N=14) | 97.2 (73.8-120.7) | 86.1 (62.7-109.6) | | |
| p [‡] | - | 0.82 | | |
| Liver, total hilus (%) | | | | |
| Omnivore (N=18) | 2.9 (1.6-4.2) | 4.2 (2.9-5.5) | 0.47 | 0.04 |
| Vegetarian (N=21) | 3.9 (2.7-5.1) | 3.8 (2.6-5.0) | | |

| | | | | |
|--|---------------------|---------------------|------------------|------------------|
| Vegan (N=14) | 2.9 (1.4-4.4) | 2.5 (1.0-3.9) | | |
| p [‡] | - | 0.003 | | |
| Liver Segment 6 (%) | | | | |
| Omnivore (N=18) | 79.6 (58.9-100.3) | 75.4 (54.4-96.4) | 0.08 | 0.91 |
| Vegetarian (N=21) | 75.4 (54.4-96.4) | 87.3 (68.2-106.5) | | |
| Vegan (N=14) | 97.2 (73.8-120.7) | 86.1 (62.7-109.6) | | |
| p [‡] | - | 0.82 | | |
| Kidney total (%) | | | | |
| Omnivore (N=18) | 1.9 (1.6-2.2) | 2.0 (1.7-2.3) | 0.56 | 0.88 |
| Vegetarian (N=21) | 1.7 (1.4-1.9) | 1.8 (1.5-2.0) | | |
| Vegan (N=14) | 1.7 (1.4-2.) | 1.8 (1.5-2.1) | | |
| p [‡] | - | 0.70 | | |
| Kidney lower (%) | | | | |
| Omnivore (N=18) | 1.7 (1.5-1.9) | 1.9 (1.8-2.2) | 0.28 | <0.001 |
| Vegetarian (N=21) | 1.7 (1.4-1.9) | 1.7 (1.5-1.9) | | |
| Vegan (N=14) | 1.9 (1.6-2.1) | 1.4 (1.2-1.7) | | |
| p [‡] | - | <0.001 | | |
| eGFR, ml/min/1.73 m² | | | | |
| Omnivore (N=18) | 118.3 (110.9-125.7) | 107.9 (100.5-115.4) | <0.001 | 0.02 |
| Vegetarian (N=21) | 118.4 (111.6-125.3) | 118.5 (111.6-125.3) | | |
| Vegan (N=14) | 125.6 (117.2-134.1) | 118.9 (110.4-127.3) | | |
| p [‡] | - | 0.002 | | |

Data are presented as mean (95%CI) at baseline, and least-squares mean (95%CI) at 6 months. Analysis was conducted using a mixed model for repeated measures, adjusting for baseline values and for baseline and 6 months daily average calories, daily average proteins and daily steps.

*P value for time effect – trend over time in all arms

†P value for treatment x time interaction – evaluates if changes in one group are different from the changes in other groups

‡P value for comparison between groups at each moment

HOMA – Homeostatic Model Assessment for Insulin Resistance, HDL – High Density Lipoprotein, LDL – Low Density Lipoprotein




Figure 1. Study design




Figure 2. Systolic and diastolic blood pressures evolution during the follow-up across the three groups




Figure 3. Kidney and liver magnetic resonance imaging-proton density fat fraction value evolution during the follow-up across the three groups